ENDV (Endonovo Therapeutics) EV-to-EBIT: -5.80 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Endonovo Therapeutics EV-to-EBIT?

Endonovo Therapeutics ENDV EV-to-EBIT is -5.80 as of Jul. 15, 2026. Among 372 Biotechnology companies, Endonovo Therapeutics ranks worse than 268816.94% on this metric.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Endonovo Therapeutics's Enterprise Value is $7.08 Mil. Endonovo Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was $-1.22 Mil. Therefore, Endonovo Therapeutics's EV-to-EBIT for today is -5.80.

The historical rank and industry rank for Endonovo Therapeutics's EV-to-EBIT or its related term are showing as below:

ENDV' s EV-to-EBIT Range Over the Past 10 Years
Min: -5.8   Med: 0   Max: 0
Current: -5.8
ENDV's EV-to-EBIT is ranked worse than
100% of 372 companies
in the Biotechnology industry
Industry Median: 13.35 vs ENDV: -5.80

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Endonovo Therapeutics's Enterprise Value for the quarter that ended in Jun. 2025 was $7.09 Mil. Endonovo Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 was $-1.22 Mil. Endonovo Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -17.22%.

Endonovo Therapeutics  (OTCPK:ENDV) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Endonovo Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2025 ) =EBIT / Enterprise Value (Q: Jun. 2025 )
=-1.221/7.08905824
=-17.22 %

Endonovo Therapeutics's Enterprise Value for the quarter that ended in Jun. 2025 was $7.09 Mil.
Endonovo Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endonovo Therapeutics EV-to-EBIT Related Terms

Endonovo Therapeutics EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Endonovo Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endonovo Therapeutics EV-to-EBIT Chart

Endonovo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.22 -3.82 -0.64 1.20 -4.54

Endonovo Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.95 -3.05 -4.54 -5.12 -5.81

ENDV vs RGBP, SIGY, CNBX: EV-to-EBIT Comparison

For the Biotechnology subindustry, Endonovo Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endonovo Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's EV-to-EBIT falls into.


Endonovo Therapeutics EV-to-EBIT Calculation

Endonovo Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=7.077/-1.221
=-5.80

Endonovo Therapeutics's current Enterprise Value is $7.08 Mil.
Endonovo Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of -5.80 mean?
Endonovo Therapeutics (ENDV) has a EV-to-EBIT of -5.80 as of Jul. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Endonovo Therapeutics and its competitors. According to the industry distribution chart, Endonovo Therapeutics ranks #999999 out of 372 companies in the Biotechnology industry.
Is Endonovo Therapeutics' EV-to-EBIT too high?
Endonovo Therapeutics' current EV-to-EBIT is -5.80. Based on the distribution chart, Endonovo Therapeutics ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Endonovo Therapeutics' EV-to-EBIT compare to RGBP and SIGY?
According to the Biotechnology industry distribution chart, Endonovo Therapeutics ranks #999999 out of 372 companies for EV-to-EBIT. This places Endonovo Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 13.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.35, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Endonovo Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Endonovo Therapeutics's current EV-to-EBIT is -5.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current EV-to-EBIT of -5.80. The current EV-to-EBIT is -5.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current EV-to-EBIT is -5.80 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Endonovo Therapeutics Business Description

Address 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.